Insta
Russia First Nation To Successfully Complete Human Trials Of A Potential COVID-19 Vaccine
Representative Image (Pic via Twitter)
In a major positive development in the global fight against COVID-19, Russia has become the first nation to have completed the world's first-ever clinical trial of a potential vaccine candidate on humans, reports Economic Times.
The vaccine has delivered effective results and as per the report the subjects who had been exposed to the medication will soon be discharged on 15 and 20 July. The trials were conducted by Russia's Centre for Clinical Research on Medications at Sechenov University.
Sharing details on the development, chief researcher Elena Smolyarchuk said, "The research has been completed and it proved that the vaccine is safe."
The first stage of the research on the vaccine had involved a group of 18 volunteers, and the second group which was subjected to the vaccine comprised of 20 volunteers. Post-vaccination, these people were to remain in isolation for a span of 28 days.
Meanwhile, it should be noted that the authorities have not spelt out any details on when the vaccine would enter commercial production stage.
As of now, as per the World Health Organisation (WHO), there are at least 21 vaccines which are presently undergoing key trials across the globe.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
